Wegovy vs Zepbound: Which GLP-1 Is Right for Seniors on Medicare?

If you qualify for GLP-1 coverage through the Medicare Bridge program, you may have a choice between two medications: Wegovy and Zepbound. Both are FDA-approved for chronic weight management, both are covered under the Bridge program at a $50 monthly copay, and both have produced impressive results in clinical trials. But they are not identical. They work through different mechanisms, have different side effect profiles, and may suit different patients depending on health history and treatment goals. This article compares them side by side so you can have an informed conversation with your doctor.

What is the difference between Wegovy and Zepbound?

The core difference is the active ingredient and how it works in your body. Wegovy contains semaglutide, which mimics a single gut hormone called GLP-1. Zepbound contains tirzepatide, which mimics two gut hormones — GLP-1 and GIP. This dual-action mechanism is why some researchers describe tirzepatide as a twincretin rather than a simple GLP-1 agonist.

Both medications reduce appetite, slow stomach emptying, and help regulate blood sugar. But the addition of GIP activity in Zepbound may provide additional metabolic benefits, including enhanced insulin sensitivity and potentially greater fat loss relative to muscle loss — though research on this distinction in older adults is still limited.

How much weight can seniors expect to lose on each medication?

The major clinical trials provide the best comparison, though it is important to note that these trials included adults of all ages and were not designed specifically for seniors.

Wegovy (semaglutide) — STEP trials

In the STEP 1 trial, participants taking semaglutide 2.4 mg lost an average of 14.9 percent of their body weight over 68 weeks, compared to 2.4 percent with placebo. For a 220-pound person, that translates to roughly 33 pounds. Subgroup analyses showed that older participants also lost significant weight, though typically at slightly lower rates than younger participants.

Zepbound (tirzepatide) — SURMOUNT trials

In the SURMOUNT-1 trial, participants taking the highest dose of tirzepatide (15 mg) lost an average of 20.9 percent of their body weight over 72 weeks — roughly 52 pounds for a 250-pound person. Even at the lower 5 mg dose, average weight loss was 15 percent. These results made Zepbound the most effective weight-loss medication ever tested in clinical trials at the time of approval.

Head-to-head comparison

While no single trial has directly compared Wegovy and Zepbound at their approved weight-loss doses, the available data suggests that tirzepatide (Zepbound) produces greater average weight loss than semaglutide (Wegovy). However, individual results vary significantly. Some patients respond better to one medication than the other, and your doctor may recommend starting with Wegovy if it has a longer safety track record or if your medical history favors semaglutide.

Side effects: how do Wegovy and Zepbound compare?

Both medications share similar gastrointestinal side effects because they both act on the GLP-1 pathway. The most common side effects for both include:

• Nausea — the most frequently reported side effect for both, especially during dose escalation
• Diarrhea
• Constipation
• Vomiting
• Abdominal pain
• Reduced appetite (this is also the intended effect)

In clinical trials, nausea rates were roughly similar between the two medications, though some analyses suggest that Zepbound may cause slightly less nausea at comparable efficacy levels. Both medications use a gradual dose-titration schedule specifically to minimize these side effects — you start at a low dose and increase slowly over several months.

For seniors, the side effects that matter most are those that can lead to secondary complications: nausea and vomiting causing dehydration, reduced food intake leading to muscle loss and nutritional deficiency, and constipation worsening existing digestive issues. These risks are the same for both medications and require the same preventive strategies — consistent hydration, adequate protein, and regular communication with your doctor.

What do both medications cost on Medicare?

Under the Medicare GLP-1 Bridge program launching July 1, 2026, both Wegovy and Zepbound are covered at a maximum copay of $50 per month. This copay cap applies regardless of your dose level and regardless of which medication you are prescribed.

Without insurance coverage, the retail prices are different:

• Wegovy: approximately $1,300 to $1,400 per month
• Zepbound: approximately $1,000 to $1,100 per month

But since the Bridge program caps both at $50, cost should not be the deciding factor for Medicare beneficiaries. The choice should be based on medical suitability, not price.

Which medication has a longer track record?

Semaglutide has been on the market longer. Ozempic (semaglutide for diabetes) was approved in 2017, and Wegovy (semaglutide for weight loss) was approved in 2021. That gives physicians roughly five years of real-world prescribing experience with semaglutide for weight management and nearly a decade for diabetes.

Tirzepatide is newer. Mounjaro (tirzepatide for diabetes) was approved in 2022, and Zepbound (tirzepatide for weight loss) was approved in late 2023. While the clinical trial data is strong, the real-world experience is shorter. Some physicians prefer to start with semaglutide for older patients specifically because the longer track record provides more confidence about long-term safety.

Cardiovascular benefits: does one have an edge?

Wegovy has a proven cardiovascular benefit. The SELECT trial, published in 2023, demonstrated that semaglutide reduced the risk of major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — by 20 percent in adults with obesity and established heart disease, independent of weight loss. Based on this data, the FDA approved Wegovy specifically to reduce cardiovascular risk in adults with obesity and heart disease.

Zepbound does not yet have equivalent cardiovascular outcome data. The SURPASS-CVOT trial studying tirzepatide and cardiovascular outcomes is ongoing but has not yet reported final results. It is possible that Zepbound will show similar or even superior cardiovascular benefits, but that has not been proven yet.

For seniors with existing heart disease or significant cardiovascular risk factors, this distinction matters. Your cardiologist or primary care doctor may specifically recommend Wegovy over Zepbound because of the established cardiovascular evidence.

How to decide: questions to ask your doctor

There is no single right answer for every patient. The best medication depends on your individual health profile. Here are practical questions to bring to your appointment:

• Do I have cardiovascular disease or significant heart risk factors? If yes, Wegovy has proven cardiovascular benefits that Zepbound has not yet demonstrated.
• How much weight does my doctor think I need to lose? If a larger amount of weight loss is the priority, the trial data slightly favors Zepbound.
• Do I have Type 2 diabetes as well as obesity? Both medications improve blood sugar, but tirzepatide (Zepbound) has shown particularly strong glucose-lowering effects in trials.
• Am I at high risk for muscle loss or sarcopenia? Discuss with your doctor whether one medication may have advantages for body composition.
• What is my doctor more experienced prescribing? A physician who has extensive experience with one medication may be better positioned to manage your care on that drug.
• What if the first medication does not work well for me? Ask about the process for switching — some patients who do not respond well to one GLP-1 do better on the other.

Can you switch from one to the other?

Yes, switching between GLP-1 medications is possible and is done under medical supervision. Common reasons for switching include inadequate weight loss on the current medication, intolerable side effects, or a change in medical circumstances such as a new cardiovascular diagnosis that favors the proven heart benefits of Wegovy. Your doctor will manage the transition, which typically involves stopping one medication and starting the other at its lowest dose to allow your body to adjust.

If you are tracking your weight, meals, symptoms, and side effects on CairnSpace, your log data can help your doctor evaluate whether a switch makes sense. Patterns in your daily tracking — consistent nausea, weight loss plateaus, or nutritional gaps — provide concrete evidence that supports clinical decisions.

Related Articles

• Does Medicare Cover GLP-1 Weight Loss Medications in 2026?
• GLP-1 Side Effects Seniors Should Know Before Starting
• What Does a GLP-1 Medication Actually Cost on Medicare After July 2026?
• How Old Is Too Old for a GLP-1? What Doctors and Research Actually Say

Sources

• STEP 1 Trial — Wilding JPH et al., Semaglutide in Adults with Overweight or Obesity, New England Journal of Medicine (2021)
• SURMOUNT-1 Trial — Jastreboff AM et al., Tirzepatide for Obesity, New England Journal of Medicine (2022)
• SELECT Trial — Lincoff AM et al., Semaglutide and Cardiovascular Outcomes in Obesity, New England Journal of Medicine (2023)
• FDA prescribing information — Wegovy (semaglutide) and Zepbound (tirzepatide)
• Centers for Medicare and Medicaid Services — Medicare GLP-1 Bridge Program coverage details (2026)